ProJenX

ProJenX

Biotechnology Research

New York, NY 500 followers

ProJenX is a clinical-stage biotech with novel, brain penetrant therapies for ALS and other neurodegenerative diseases.

About us

ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.

Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
New York, NY
Type
Privately Held
Founded
2021
Specialties
Neuroscience, Motor Neurons, and Neurology

Locations

Employees at ProJenX

Updates

Similar pages

Browse jobs

Funding

ProJenX 3 total rounds

Last Round

Grant

US$ 1.0M

See more info on crunchbase